Zeid K. Kayali

Zeid K. Kayali

Gastroenterology
2006 N Riverside Ave
Ste A
Rialto, CA 92377

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.

A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis.

Journal: Hepatology (Baltimore, Md.)
Published: December 04, 2025

Impact of Age on Mortality and Decompensation Events in Patients With Liver Cirrhosis: A Multicenter, Propensity Score Matched Study.

Impact of Age on Mortality and Decompensation Events in Patients With Liver Cirrhosis: A Multicenter, Propensity Score Matched Study.

Journal: International journal of hepatology
Published: July 19, 2025

Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions.

Pharmacokinetics and Safety of a Single Dose of Brensocatib in Participants with Hepatic Impairment and Matched Participants with Normal Hepatic Functions.

Journal: Clinical pharmacokinetics
Published: May 28, 2025

Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging-Proton Density Fat Fraction.

Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging-Proton Density Fat Fraction.

Journal: Gastro hep advances
Published: October 24, 2024

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?

Journal: Expert opinion on investigational drugs
Published: August 02, 2024

Survival and Disease Progression in Older Adult Patients With Cirrhosis: A Retrospective Study.

Survival and Disease Progression in Older Adult Patients With Cirrhosis: A Retrospective Study.

Journal: International journal of hepatology
Published: April 11, 2024

Unravelling a Mysterious Skin Lesion in a Patient with Ulcerative Colitis.

Unravelling a Mysterious Skin Lesion in a Patient with Ulcerative Colitis.

Journal: The American journal of medicine
Published: July 31, 2023

A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.

A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.

Journal: Alimentary pharmacology & therapeutics
Published: November 09, 2022

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Journal: Journal of hepatology
Published: July 21, 2021

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

Journal: Journal of hepatology
Published: July 07, 2021

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

Journal: Journal of hepatology
Published: February 20, 2020

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

Journal: Journal of hepatology
Published: November 19, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026